insights_auto
Kodėl „GIS“ sumažėjo 2,25%?
Įsigilintichevron_right
GIS:ETR
Gilead Sciences, Inc
128,70 €
arrow_downward
−2,25%(−2,96) 1 D.
10-02, 17:35:54 GMT+2 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „GIS“ įžvalgos...
Atidaryti
131,24 €
Aukšta
132,16 €
Žema
128,70 €
Rinkos kapitalizacija
179,47 mlrd.
Vid. kiekis
688,00
Apimtis
1,26 tūkst.
52 sav. aukšta
136,24 €
52 sav. žema
92,41 €
Darbuotojų skaičius
17 tūkst.
Atidaryti
131,24 €
Aukšta
132,16 €
Žema
128,70 €
Rinkos kapitalizacija
179,47 mlrd.
Vid. kiekis
688,00
Apimtis
1,26 tūkst.
52 sav. aukšta
136,24 €
52 sav. žema
92,41 €
Darbuotojų skaičius
17 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
MarketBeat
·
prieš 19 minučių
31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional
Yahoo Finance
·
prieš 10 valandų
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
AD HOC NEWS
·
prieš 17 valandų
Zacks cuts Gilead Sciences stock to Hold rating
AD HOC NEWS
·
prieš 1 dieną
Gilead Sciences stock after-hours at EUR 131.85: plus 0.62 percent after the Xetra close
Profilis
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Apie „Gilead Sciences, Inc“
Generalinis direktoriusDaniel O'Day
Darbuotojai17 tūkst.
Įkurta1987-06-22
Pagrindinė būstinėFoster Sitis, Kalifornija, Jungtinės Valstijos
Sektorius-
Svetainėgilead.com